Cambridge, UK, December 7th 2011 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announces that it will be hosting an international training seminar on 23rd February 2012 in Ahmedabad, India. The event will address the regulatory challenges for 2012 and their impact on marketing authorisation.

As well as an overview of the latest changes in European Regulatory Procedures, the day will focus on the implementation of electronic submission of medical production information in the new EU requirements of the Pharmacovigilance legislation.

The full-day course will cover the evolution of the registration systems available for approval of products in the EU, together with major changes in New Medicines Legislation. These changes include regulatory procedures, access to Centralised and Mutual Recognition Procedures and reduction in Regulatory Data protection.
There will also be discussion on regulatory strategy which impacts on commercial, business and licensing arrangements and will be of importance to those responsible for business development.

ELC GROUP’s Advisory Board member, Dr. Paolo Biffignandi MD, PhD, QPPV, FTOPRA, will host the day. Dr. Biffignandi has over 30 years’ experience in Regulatory Affairs and pharmacovigilance. He is a past President and now Fellow of The Organisation for Professionals in Regulatory Affairs (TOPRA) and a renowned physician, with PhDs in endocrinology and pharmacology. He is also an Overseas Fellow of the Royal Society of Medicine (UK) and provides a regulatory column for EPM magazine (European Pharmaceutical Manufacturer).
Speaking about seminar, Marco Rubinstein ELC GROUP CEO said: “We are delighted to be hosting this event and sharing Paolo’s expert knowledge with an ever increasing audience. This event will be a fantastic opportunity for attendees to meet experts in the complex field of EU Pharma regulation.”

You can register to attend online here: http://www.elc-group.com/index.php?option=com_content&view=article&id=57&Itemid=48

—-ends—-

Press contacts
Akhil Jain
ELC Group
ajain [at] elc-group [dot] com
Phone: +420 22 491 00 00

Nicky Denovan
EvokedSet PR
nicky [at] evokedset [dot] com
Phone: +44 (0)7747 017654

About ELC Group (www.elc-group.com)
ELC GROUP is a leading global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries as well as REACH services to the Chemical industry. It helps companies that lack the resource (skills and knowledge) to cost-effectively deliver regulatory affairs.

ELC Group provides full-service, multi-lingual consulting and cost-effective solutions to regulatory approvals using experts with in-depth knowledge and experience throughout the world. The team ranges from former FDA investigators to individuals with over 30 years of industry experience with broad capabilities. This includes integrated advanced technologies, regulatory affairs consulting and commercialisation services.

Mumbai Based Pharmaceutical Major Aanjaneya Lifecare (BSE code (533412), the largest Quinine producers in world is yet again on the news. Sources close to Pharmaleaders (www.pharmaleaders.co.in ) reveal that Aanjaneya Lifecare is on the final stage of negotiations with a domestic formulation unit to widen its product baskets. Market is abuzz as the news of Aanjaneya posted a rapid strides in its balance sheet with Results for the half year ended for the second quarter ended September 30, 2011, the revenue of the company rose by 39% to Rs 1109 million from Rs 799 million for the same period last year. With this, the total revenue during the first half rose by 36% to Rs 2112 million & the net Profit for the second quarter increased 46% to Rs123 million from Rs 84 million for the same quarter of the previous fiscal year. With this the net profit for the first half of the current fiscal shot up by 51% to Rs. 236 million as against Rs. 156 million for the corresponding period of last year.

If the statement by the Board Chairman Dr Kannan to be believed while addressing the AGM “Our Company has showed an impressive growth in the current year and we promise our investors and stakeholders that we will continue to do the same in future” is to be understood in the right context, one can clearly say that Aanjaneya with focus on anti-malarial, and finished dosage forms (FDFs), has zeroed on a domestic unit with presence in cough cold, pain management segment. It is quite evident as the company in last six months was looking at some established Brands into its product baskets. The size of the Acquisition & deal value & the acquiring company is believed to be kept in top secret as many attempts by Pharmaleaders to reach out the company failed & calls remain unanswered. The News, if to be believed in right context, though unconfirmed officially, could be a game changer for Aanjaneya Lifecare given the aggressive plans the company is looking at to expand.

The company recently raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities alongwith the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed, company sources informed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment.
The Author is Editor-In-Chief of Pharmaleaders Magazine. He can be reached at satya.brahma@pharmaleaders.co.in

LSK Global provides clinical services for phase I/II/ III studies. LSK Global was established in 2000. Talking about the alliance, Ashok Ghone, Ph.D. (VP, Global Services) mentioned that MakroCare and LSK Global operate in key strategic regions of USA & Asia and the collaborative relationship between two companies provides opportunity, now that MakroCare can extend support, to their potential & existing customers that need services in Korea, utilizing LSK’s local know-how. LSK Global will be utilizing MakroCare’s USA and other Asian region strengths effectively.

MakroCare, established in 1996,  is an international Drug Development and Commercialization  services firm that is dedicated to support pharma, biotech and medical device companies to achieve high-level of performance. MakroCare has 5 divisions – Consulting, CRO, SMO, Informatics, and Commz to support various aspects of product life cycle management. MakroCare has teams positioned worldwide in these divisions supporting several services including management consulting, regulatory affairs, risk management, study feasibility, clinical trial management (early to late phase), biometrics (CDM, EDC, biostatistics, SAS programming, medical writing), QA audits, safety/PV, site management, patient recruitment and retention, and informatics

Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia, with 30,000–50,000 cases reported annually. Case-fatality rates range from 0.3% to 60% and depends on the population and on age. There is no specific treatment for Japanese encephalitis and therapeutic management is only supportive. This year, large numbers of cases and deaths have been reported in Eastern Uttar Pradesh, Assam & Bihar. Also the southern states have reported large number of cases as per government reports.

The results of the study would be submitted to the Indian regulatory authority for licensure. With this vaccine coming into the Indian market there would be an efficacious and safe vaccine for use in children in India and other parts of Asia.

BE’s inactivated JE vaccine (JEEV®)is not produced in mouse brains, but in vitro using cell culture hence there is reduced risk of rare autoimmune neurological complications. Unlike mouse brain derived vaccines which require three doses given at 0, 7–14 and 28–30 days, BE’s inactivated JE vaccine, like IXIARO™, has an unique advantage of offering a convenient two dose schedule (day 0 & 28), better safety profile and efficacy. The route of administration is intramuscular unlike the mouse brain derived vaccines which are administered subcutaneously.

Dr. Vijay Kumar Datla, Chairman and Managing Director of Biological E. Limited added: “We are excited about the successful completion of our phase-II/III clinical study which enables us to offer this novel and safe vaccine to combat Japanese Encephalitis not only in India but also across Asia. There is also an urgent need to respond to the JE epidemic throughout India and Asia where large-scale immunization is critical. Our strategic partnership with Intercell furthers the aim of ensuring a sustainable supply of our vaccine at the earliest.”

For further information, media may please contact:
Mr. Joseph Clement Chettiar, Sr General Manager (Marketing & Sales), Biological E Ltd., Hyderabad. Cell: +91 9676461717, Email: joseph.c@biologicale.co.in

Evolva’s shareholders approved the capital increase required for the acquisition in the Annual General Meeting (“AGM”) of Evolva on 18 May 2011. As announced on 5 April 2011, the acquisition of Abunda requires an upfront investment of 25 million newly issued Evolva shares. This equals close to 18% of Evolva’s currently outstanding capital. SIX Swiss Exchange has cleared the Listing Prospectus related to the issue of the new Evolva shares so that the transaction could be executed.

The selling Abunda shareholders have agreed to submit the Evolva shares they will receive, to the Lock­up and Coordinated Sale mechanism. This structure was set up by Evolva’s core investors in December 2010 in order to facilitate the gradual release of Evolva’s lock­up and increase the stock’s free­float.

Evolva’s shareholders elected two new members for the Board of Directors in the AGM of 18 May 2011: Ganesh Kishore and Stuart Strathdee. The election was conditional upon the closing of the Abunda acquisition. Upon closing, the election of the two Board members will be confirmed. In addition, the CEO of Abunda, Simon Waddington, will join Evolva’s Group Management Team.

Evolva Biotech Private Limited
www.evolva.com
India: 401-405, 4th Floor, TICEL Bio Park Limited, Taramani, Chennai-600113, Tel: +91-44-2971050
USA: 2440, Embarcadero way, Palo Alto, CA 94303, Mob: +1-650-644-9212

Goose (www.goose.co.in), a leading innovator of Business Reengineering Solutions for Global Pharmaceutical Industry has announced the launch of Procon™ Tracker, a new indigenously developed Track and Trace solution to help Pharma industries meet the new regulatory packaging guideline, detect counterfeit and protect their brand reputation. Procon™ Tracker is a new addition to Goose wide range of Procon solutions adopted by several leading global pharma companies to increase business processes efficiency.

Procon™ Tracker features highly robust encrypted serialization and package authentication capability designed to ensure consumer safety, reduce counterfeiting & diversion and meet multiple stakeholder expectations throughout the product supply chain from the point of manufacturing to consumer end.

Making the announcement Deb Pattnaik, Founder of Goose said the recent directive from the government to Pharma Industry to implement track and trace automatic identification process to offset counterfeits opens an opportunity for our product Procon™ Tracker. We found the Pharma Industry is eager to meet the new regulatory compliance norms deadline without disrupting packaging quality process and Procon Tracker is designed precisely to meet these expectations.

Counterfeit drugs entering the supply chain is a growing problem around the world. Consumer and patient safety is crucially important within the healthcare and pharmaceutical industries, as well as, the eroding bottom lines of most pharmaceutical companies due to counterfeit medications infiltrating the supply chain. The Center for Medicines in the Public Interest http://www.cmpi.org/) estimates that “globally, counterfeit pharmaceutical commerce will grow to become 16% of the aggregate size of the legitimate industry, a six percentage-point increase from 2004. This illegal business will generate $75 billion in revenues for its owners in 2010, a 92% increase from 2005.”

“We are excited about the potential of Procon™ Tracker and its addition to a wide range of high performance solutions we offer to the Global Pharma industry,” Deb added. “As a deep domain player, we consistently respond to new requirements of our customers with products that scale up their business advantage. Procon™ Tracker is a robust easy to integrate Track and Trace solution designed to meet the Government compliance and multiple stakeholder expectations.”

Goose offers a wide range of Pharma Industry specific solutions such as Artwork, Project, Consumable Regulatory Affairs Management and Portfolio Management Solutions. Currently, its customers include large Indian and multinational pharmaceutical companies.

Goose is in talks with its existing and potential customers and expects wide acceptance and adoption Procon™ Tracker in the industry.

Procon™ Tracker: Product Highlights

The CFR Part 11 compliant Procon™ Tracker supports pedigree (an electronic record keeping requirement) and is capable of multi printer interface. It also supports automated and manual lines with added competency to work offline when there are no bar code capable printers. Procon™ Tracker also features ERP integration along with a module tenable verification through SMS, Web or IVR. The solution can generate billions of Unique Numbers with minimum 6 characters that is expandable based on customer need.

Other features of Procon™ Tracker include proprietary algorithm that considers several parameters specific to company, batch and computer. Procon™ Tracker is scalable and has quick response time for generation and validation of serial numbers. Procon™ Tracker supports GS1 standards

Evolva plans to acquire its R&D partner Abunda Nutrition, Inc. Evolva and San Francisco-based Abunda have collaborated on the development of Abunda’s next-generation nutritional ingredients since 2009. One part of this collaboration has focused on advancing highly purified forms of the natural high intensity sweetener Stevia, produced via fermentation in yeast. This process bypasses the complex logistics associated with the traditional cultivation, processing and refining of Stevia plants, and allows pure Stevia components to be produced.

The value of the global sweetener market is currently estimated at USD $70 billion, with sugar the dominant product. Within this market, Stevia-based sweeteners are the fastest growing segment, with demand driven in part because Stevia extracts have 200-300 times the sweetness of sugar, but also because of increasing consumer demand for low-carbohydrate-low-sugar for health, wellness, and performance products. By enabling the introduction of new sweetener products with compelling health, taste and other benefits for consumers, fermentation-derived Stevia can potentially take an important part of the overall sweetener market.

In addition to Stevia, Evolva will obtain full ownership of certain additional development-stage compounds with relevance in cardiovascular health and other nutrition sectors. Clinical nutrition trials are being conducted on selected compounds.

Under the terms of the proposed merger, Evolva will acquire 100% of the share capital of Abunda in return for 25 million Evolva shares (12.9% of Evolva’s share capital post transaction, fully diluted). If certain value-creating milestones are achieved in the 19 months after closing, Abunda shareholders are entitled to receive up to an additional 12 million shares and, for three years afterward, a low-teen percentage share of cash returns from the Abunda assets. Abunda brings sufficient cash for the development its product portfolio through year-end 2012, and as such the transaction does not affect Evolva’s cash runway. The intended transaction would increase Evolva’s expected cash outflow in 2011 from CHF 20m to CHF 22m (2010: CHF 18.1m).

The terms of the transaction have been approved by the Boards of both companies. The transaction is subject to approval of the required capital increase by Evolva’s shareholders and is expected to close in late Q2 or early Q3 2011.

For more information kindly visit our website www.evolva.com

March 31, 2011 – Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark’s Biologics Research Centre located in Switzerland.

The disease areas primarily targeted by GBR 401 are lymphomas and leukemia’s of B-cell origin.

Lymphomas are cancers originating from the lymphatic system. Non-Hodgkin’s lymphoma (NHL), a type of B cell lymphoma, is the most common form of blood cancer. Leukemia is a cancer of the white blood cells. Within the seven major markets comprising of US, Europe Top 5 markets and Japan, new cases of NHL and leukemia’s of B cell origin were estimated at 126,000 and 34,000 respectively. In addition the CD19 target holds potential for treatment of inflammatory disorders such as rheumatoid arthritis. GBR 401 shows great promise to emerge as a valuable therapeutic option to treat patients affected with B-cell malignancies. GBR 401 has demonstrated strong anti-tumour potency and antiproliferative
apoptotic activity in several in-vitro and in-vivo studies. CD19 is known to be
expressed earlier and more broadly in B-cell development than CD20, the latter being the target of the worlds second largest selling anti-cancer biotech product rituximab (Rituxan® / MabThera®) whose annual 2010 sales were in excess of US$6 billion. Glenmark will pursue further development of GBR 401 to accelerate its entry into clinical trials.

Commenting on this milestone, Mr. Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals mentioned “We are excited to announce GBR 401, which has been developed completely inhouse leveraging our biologics antibody know‐how. We are confident that the antibody expertise and product development capabilities of the Switzerland Biologics Research Centre will continue to enrich the Glenmark discovery pipeline.”

“Targeting CD19 is a promising approach to treat B‐cell malignancies. Further, GBR 401 has been developed using a technologically advanced platform that greatly enhances the efficacy of the antibody” said Dr. Michael Buschle, President‐Biologics,

Glenmark Pharmaceuticals S.A.,
Switzerland.

About CD19 Target:-
Antibody inhibitors or cytotoxic antibodies against CD19 have the potential to treat a plethora of B cell or antibody-mediated diseases including malignancies and autoimmune diseases. CD19 forms part of the B cell co-receptor in conjunction with CD81 and CD21. It has no known ligand and is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. It is present on B cells from the earliest recognizable B-lineage cells during development within the bone marrow to B-cell blasts but is lost on maturation to plasma cells. CD19 is used as the primary marker for the identification of B cell malignancies so its use as a target is understandable and as the B cell is also the producer of autoimmune antibodies in diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) then the removal of these cells will also benefit sufferers.

Glenmark’s Novel Biologics Entity pipeline:-
With the addition of GBR 401 to the pipeline, Glenmark will now have four monoclonal antibodies in the Novel Biologics Entity (NBE) pipeline. First, GBR 500, a monoclonal antibody represents a first-in-class opportunity indicated for the treatment of Inflammatory Bowel Disease (IBD) and Multiple Sclerosis (MS). GBR 500 has completed Phase I trials in the US and is the first novel monoclonal antibody developed by an Indian Company in the US. The second monoclonal antibody product, GBR 600, is a highly specific platelet inhibitor for the prevention of von Willebrand Factor (vWF) mediated diseases. GBR 600 has received approval for initiation of Phase I trials in Europe. Further, in Sept 2010 Glenmark received the exclusive license to the monoclonal antibody BXL1H5 i.e. GBR 900 including the exclusive target license to commercialize monoclonal antibodies against TrkA receptor for pain from Lay Line Genomics, an Italian based Company. TrkA is a promising target and monoclonal antibodies specific for TrkA represent a first- in-class opportunity for the treatment of chronic pain, which has a high level of unmet need. GBR 900 is in the pre-clinical stage of development and will be developed further by Glenmark Swiss R&D center

Glenmark Pharmaceuticals Limited India

For Sample Pages, please click or add the below link to your browser:

http://gbiresearch.com/RequestSamplePages.aspx?ID=Clinical-Trial-Endoints-in-Oncology-Inclusion-of-Surrogate-Endpoints-and-Shorter-Endpoints-Will-Ensure-Faster-Clinical-Trials-in-Oncology&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

The major marketed drugs after 1990 approved for head and neck cancer were Erbitux (cetuximab), Taxotere (docetaxel), Oncorine (H101, Modified Adenovirus) and Gendicine (Recombinant Human Ad-P53). The primary and secondary endpoints in these included median and overall survival rate, progression-free survival and complete response rate. Similarly, the major marketed drugs after 1990 approved for ovarian cancer were Altretamine (Hexalen), Gemcitabine (Gemzar), Hycamtin (Topotecan hydrochloride) and Yondelis (trabectedin). The primary and secondary endpoints of these drugs included overall and complete response rate, progression-free survival, time to response and overall survival.

GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Endpoints in Oncology – Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology”. It provides in-depth analysis of the endpoints and application of endpoints in oncological clinical trials. The report analyzes the four major therapeutic area involved, which include colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer. The report includes analysis of endpoints of major oncological market products and profiles. In addition to marketed products, the Phase III and Phase II clinical trials are also analyzed in terms of percentage cases. Analysis of terminated trials is also included in the report. Furthermore, the report provides competitive benchmarking for the leading companies and profiling of major companies in the oncology market.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:

http://gbiresearch.com/Report.aspx?ID=Clinical-Trial-Endoints-in-Oncology-Inclusion-of-Surrogate-Endpoints-and-Shorter-Endpoints-Will-Ensure-Faster-Clinical-Trials-in-Oncology&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

For more details contact:

North America:             +1 646 395 5477

Europe:                        +44 207 753 4299

+44 1204 543 533

Asia Pacific:                  +91 40 6616 6782

Chennai, India, 15 February 2011; SGS Life Science Services is pleased to announce that its facility in Chennai, India has received prequalified status from the World Health Organization (WHO), effective January 17, 2011. WHO prequalification indicates that the laboratory has met established global quality guidelines on Good Practices for National Pharmaceutical Control Laboratories and Good Manufacturing Practices (GMP).

Passing the WHO’s prequalification program also means that approved labs are registered on the WHO website as able to test and release life saving drugs treating diseases such as HIV/AIDS, tuberculosis, malaria and reproductive health medicines. “Receiving prequalification demonstrates our commitment to continually raising the standards of our laboratories”, said Ulrich Markens, Vice President Corporate Quality & Compliance for SGS Life Science Services. “Presently, only 19 laboratories worldwide are prequalified by the WHO and SGS is honoured to be one of them.”

SGS began its Life Science Services operations in Chennai in 2005 to provide analytical support to the rapidly growing pharmaceutical industry in India. The laboratory continually works to improve the quality in its operations. It received ISO 17025 certification in 2005, is a GLP Certified Laboratory by National GLP Monitoring Authority of India and was inspected and registered with the US-FDA since 2007. The Life Science Services portfolio offering in Chennai includes: analytical chemistry – quality control release, environmental monitoring, extractables and leachables, medical device testing, method development and validation, microbiological testing, in vitro safety testing and stability studies.

xx

SGS in India

Founded in 1950, SGS India now employs more than 3000 highly motivated, multi-disciplined professionals and utilizes some of the most sophisticated communication networks. With years of local experience and a vast network of offices and laboratories, SGS India offers high level expertise in the testing, verification and inspection of products from a wide range of industries.

The SGS team also contributes to the enhancement of clients’ management standards through training, consultation and certification. SGS is committed to working closely with clients in order to help them improve efficiencies and reduce business risks by providing swift and simple one-stop solutions.

About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognised as the global benchmark for quality and integrity. With more than 64,000 employees, SGS operates a network of over 1,250 offices and laboratories around the world.

xx

Media Contact

Benz Thomas

Manager – Corporate Communications

SGS India Private Limited, 250 Udyog Vihar Phase IV
Gurgaon 122 015, Haryana, India

Phone: +91 124 677 6259
Mobile: +91 99 71 17 73 91
Fax: +91 124 239 9763 to 64
E-mail: benz.thomas@sgs.com

DELHI, India, 03 February 2011 – Salesforce, the enterprise cloud computing company, today announced that India’s second largest pharmaceutical company, Dr. Reddy’s Laboratories, has deployed Salesforce CRM across 200 users within 60 days.

Dr. Reddy’s decided to move its Active Pharmaceutical Ingredients (API) marketing business to the cloud in order to improve visibility into its deals pipeline, track its end-to-end sales cycle and better analyze its sales funnel.

Dr. Reddy’s implemented Salesforce CRM with the help of IT business consulting firm Bodhtree, who used its data integration engine MIDAS to integrate with existing Mail, Calendar, and SAP systems, By streamlining its sales business on Salesforce, Dr. Reddy’s expects to increase revenue by more than 30%.

Comments on the News

• “We eliminated bottle necks within the sales cycle almost immediately because of the greater visibility we gained into sales performance,” said B.V. Srinivas, Deputy CIO, Dr. Reddy’s Laboratories. “Salesforce’s ability to seamlessly integrate data captured offline with online systems, is of immense help to our field sales team who need to track and update customer data on regular basis but do not have access to internet connectivity at all times. Salesforce delivers all of the benefits of a world-class CRM system within a cost-effective ‘pay as you go’ model, which fits perfectly with Dr. Reddy’s ‘quality without the cost’ ethos.”
• Salesforce Asia Pacific Senior Vice President for Corporate Sales Lee Thompson said, “Dr. Reddy’s is a prime example of how cloud integration can add value to legacy systems. With cloud computing, there are no hidden costs in terms of hardware, software, or 22% annual maintenance fees. You know exactly what you’re going to pay for, and people just love using Salesforce CRM.”

About Salesforce

Salesforce is the enterprise cloud computing company. Based on salesforce’s real-time, multitenant architecture, the company’s platform and CRM applications have revolutionized the way companies collaborate and communicate with their customers, including:

• The Sales Cloud, for sales force automation and contact management
• The Service Cloud, for customer service and support solutions
• The Jigsaw Data Cloud, for ensuring data integrity and quality
• Salesforce Chatter, for social collaboration
• The Force platform, for custom application development
• Database, the world’s first enterprise cloud database
• The App Exchange, the world’s leading marketplace for enterprise cloud computing applications

Salesforce offers the fastest path to customer success with cloud computing. As of October 31, 2010, Salesforce manages customer information for approximately 87,200 customers including Allianz Commercial, Dell, Japan Post, Kaiser Permanente, KONE, and SunTrust Banks.

Any unreleased services or features referenced in this or other press releases or public statements are not currently available and may not be delivered on time or at all. Customers who purchase Salesforce applications should make their purchase decisions based upon features that are currently available. Salesforce has headquarters in San Francisco, with offices in Europe and Asia, and trades on the New York Stock Exchange under the ticker symbol “CRM.” For more information please visit http://www.bodhtree.com/services-it-crmconsulting.shtml

New Delhi, December20, 2010: Johnson & Johnson Limited today announced the launch of Nicorette®, the number one smoking cessation brand worldwide, in India. Nicorette® Gum is a sugar-free nicotine gum that doubles your chances to stop smoking altogether by reducing nicotine cravings that make kicking the habit so difficult. Nicorette®will be available in packs of 4mg (10 gums), which are for “heavy smokers” through a doctor’s prescription and as an OTC product of 2mg (4 & 10 gums) for “light smokers”, beginning December 25, 2010.

A Nicotine Replacement Therapy (NRT) product, Nicorette® provides therapeutic and clean nicotine, slowly and in lesser quantities as compared to a cigarette, but also just enough to satisfy the cravings. NRT substitutes some of the nicotine obtained from smoking, thereby controlling craving and withdrawal symptoms, and thus preventing relapse to smoking. More importantly, unlike tobacco smoke, it delivers nicotine which is devoid of any harmful chemicals like tar, irritants and carbon monoxide, and hence is safer than smoking a cigarette.

According to Tushar Murdeshwar, General Manager Marketing, Consumer Division, Johnson & Johnson Ltd, India, “Nicorette is an iconic global brand from Johnson &Johnson Ltd. that supports our core value of helping people stay healthy. We believe there is a need for such a product in India. Nicorette is not just a chewing gum but a complete infrastructure and support system that can help a smoker quit and lead a healthier life, benefitting him and society at large.”

In India, the awareness of NRT as an effective and safe partner in the struggle to quit smoking is very low and the usage is even lower explaining why 81% of the current smokers have at some point in the past tried to quit but have relapsed, according to the latest AC Nielson Survey. Nicorette®, the global leader in Nicotine Replacement Therapy, as per the Euro monitor sales report 2009, has successfully helped millions of people quit globally and will now be available in India to support the smoker’s willpower and double his/her chances of remaining smoke free.

Avers Gautam Suri, General Marketing Manager, Consumer Division, Johnson & Johnson Ltd, India, “Globally smoking is the single largest cause of preventable death. Smoking causes more deaths worldwide than AIDS, legal drugs, illegal drugs, road accidents, murder and suicide combined. With over 24% of the Indian male population currently smoking, Nicorette®, the world’s No. 1 tobacco cessation brand, can be the partner of choice to help consumers take control and break free from tobacco in India. We think it will play a critical role by helping consumers in the journey to quit smoking. We truly believe that Nicorette® will provide both, physiological and psychological support, ultimately improving the overall health of our nation, tying back to the core mission of Johnson & Johnson Ltd.”

Using willpower alone has so far been the most popular method in India to try and quit smoking. Dr. Sajeela Maini, Tobacco Cessation Specialist*, explains, “This is really the need of the hour in India. Today smokers must have a 360 degree environment of support. NRT addresses the issue of physical addiction to nicotine and allows the smoker to focus his/her will-power on combating the habits and triggers that perpetuate the addiction to cigarettes.”

SMOKING IN INDIA

Some facts…

Who and How Many

* There are over one billion smokers globally, with an estimated 110 million in India. The estimated number of tobacco users in India is 275 million.
* One-third of all adults in India (35%) use tobacco in some form or the other. While 21% use only smokeless tobacco 9% only smoke and 5% smoke as well as use smokeless tobacco.
* Prevalence of tobacco use decreases with increase in education among both males and females.
* In India, tobacco consumption is widely prevalent and culturally accepted. Tobacco use among population age group of 15-24 is 18%.
* The prevalence of smoking in Indian males is 24% and consumption of chewing tobacco is more common amongst woman with a prevalence of 18% nationwide.
* Indian smokers smoke an average of 6.2 cigarettes per day and average expenditure on cigarettes for daily smokers is Rs. 399.20 per month.
* 1/4th of daily cigarette smokers smoke more than 10 cigarettes per day.

How it Works

* Each puff on a cigarette sends nicotine to the brain within 10 seconds.
* Tar and carbon monoxide from tobacco smoke harm the body by producing carboxy-haemoglobin, raising blood and plasma viscosity as well as increasing platelet aggregation.
* Tobacco dependence is perpetuated by regular doses of nicotine. Regular smoking makes it necessary to maintain certain levels of nicotine in the brain for normal functioning and pleasure derivation.
* Nicotine is one of the many components of tobacco smoke and is addictive in nature. However, other components of tobacco smoke comprising tar, irritants and carbon monoxide are the actual cause of tobacco related diseases.

Effects of Smoking

* It is estimated that every cigarette takes 11 minutes off a smoker’s life.
* Worldwide tobacco kills 1 person every 6 seconds.
* It is estimated that in the year 2015, 1, 43,963 Indians would have been diagnosed with oral and pharyngeal cancers and 91,029 would have died of the disease.

Knowledge and awareness

* The awareness about smoking causing strokes is only 49%.
* Only 64% believe that smoking causes heart attacks.
* While 85% believe that smoking causes lung cancer.
* Over 4/5th of adults believe that second hand smoke causes serious illness among non smokers.

Quitting

* 38% smokers and 35% smokeless tobacco users made an attempt to quit in the past 12 months.
* Nearly half of current smokers (47%) and smokeless tobacco users (46%) want to quit their tobacco use but a meager 2% succeed.
* The quit attempts by smokers using different cessation methods included pharmacotherapy (NRT/ prescription meds) – 4.1%, counseling/ advice – 9.2% and others (traditional meds, switching to smokeless tobacco) – 26%.
* Indian smokers are amongst the most motivated when compared to other Asian smokers to quit/reduce smoking with nearly 38% indicating that they were- extremely/very/somewhat motivated.
* Only 29% of all Indian smokers are extremely/very satisfied with the products and methods available as aids for smoking cessation.
* Medication and support from healthcare professionals can more than double the chances of quitting.

About Johnson & Johnson Limited, India

Johnson & Johnson Ltd. was founded more than 120 years ago on a revolutionary idea: Doctors and nurses should use sterile sutures, dressings and bandages to treat peoples’ wounds. Since then, we have brought to the world, new ideas and products that have transformed human health and well-being. Since our founding in 1886, we have grown to meet the health care needs of people worldwide. We are the world’s largest and most broadly based health care company, with more than 250 companies located in 57 countries around the world. Our Family of Companies is organized into several business segments comprised of franchises and therapeutic categories – Consumer Health Care, Medical Devices & Diagnostics and Pharmaceuticals.

In the more than 50 years of operating in India, Johnson & Johnson Limited has gained a reputation for delivering high-quality products. Today, we employ more than 2000 people and the businesses span Consumer, Medical Devices and Diagnostics, Pharmaceuticals and Vision Care. Johnson & Johnson Limited India is an employer of choice and is a recipient of several awards, which recognize it as one of the best employers in India.

For more information, please visit the Company’s website at www.jnjindia.com

*Dr. Maini is a member of the ACTIVE (Action for Cessation of Tobacco Initiative) panel which is sponsored and promoted by Johnson & Johnson Ltd.

For further information, please contact:

The PRactice

Astha Tandan

Email: astha@the-practice.net

Phone: +91 9820113133

Event Details

Date: January 13, 2011
Time: 12:00-16:30 GMT
Venue: Oracle UK, One South Place, London, EC2M 2RB

Event Overview
Infosys and Oracle co-host seminar on Life Sciences. Experts from Pharma Logistics Limited, Oracle, Quintiles, and Infosys present industry and business relevant sessions. The seminar will focus on:

Why Pharmas now invest in Clinical Data Warehouse platforms to ensure Regulatory Compliance and enable cross-enterprise reporting
Current trends in Electronic Data Capture in clinical trials and safety, whether on premise or hosted mode
Can Cloud Computing apply to Clinical Development?
Oracle solutions and services following the Oracle – Phase Forward combination

Session Details

Welcome Note and Introduction to Event
By Ashish Goel, Associate Vice President, Insurance, Healthcare and Life Sciences, Western Europe, Infosys Technologies
Time: 12:00-13:00 GMT

Session
Topic: Leveraging Oracle Life Sciences Suite for Managing Multiple Data Sets to Optimize New Drug Development Cycle Time
Speaker: Aaman D. Lamba, Principal Consultant, Enterprise Solutions-Oracle Practice, Infosys Technologies
Time: 15:30-16:00 GMT

Session Description
Our expert describes ways in which Oracle Life Sciences Data Hub can be used by enterprises to obtain platform independence and integrate diverse applications/data sets. The presentation will also demonstrate integration benefits, and the effectiveness of Oracle Life Sciences Data Hub as a platform to optimize drug development cycle time.

Speaker Profiles

Ashish has over 16 years of industry experience, of which 14 have been with Infosys. He has worked with several global clients in Life Sciences, Insurance, Logistics, and Retail sectors, leading customer relationships across North America, Europe, and Asia.

Aaman has over 14 years of experience in customer operations and MDM implementations. He anchors the Life Sciences competency for Infosys. He is responsible for mentoring the team, implementing strategies on Life Sciences and Clinical Data Management, and providing delivery oversight to large programs. He has managed and implemented global CRM, MDM, and Clinical Data Management programs. Aaman has been part of complex change management programs, enabling change and working with stakeholders. He has actively collaborated with Oracle for Life Sciences Solutions on the Life Sciences Hub, and co-ordinated the implementation of the Oracle Life Sciences Center of Excellence at Infosys

Please write to Kamilla_matyus@infosys.com for registration
Go to Source

San Mateo, CA – Red Herring announced its Top 100 Asia Award in recognition of the leading private companies from Asia, celebrating these startups’ innovations and technologies across their respective industries.

Red Herring’s Top 100 Asia list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.

“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Asia to the Top 100 Winners. We believe Vanuston Intelligence embodies the vision, drive and innovation that define a successful entrepreneurial venture. Vanuston Intelligence should be proud of its accomplishment, as the competition was very strong.”

Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Asia.

October 12, /IndiaPRLine.com/ Top International Experts Come Together to Offer the Latest Contemporary Knowledge on Microbiological Aspects of Sterility Assurance for Pharmaceuticals, Biotechnology and Medical Devices in this new book. Hardbound 996 pages, ISBN: 9788190646741

Injectable product manufacturing is booming because of the growth of new biopharmaceuticals and small molecule anticancer drugs. The requirements for contamination control will become even more stringent than today. Isolators or blow-fill-seal equipment have already replaced the conventional clean rooms and LAF-hoods in many production facilities. Conventional microbiological monitoring methods, requiring 3 to 5 days of incubation will become inappropriate. Equipment is already available allowing real time, simultaneous viable and non-viable counting. Sterile manufacturing facilities especially, require state-of-the-art skills to ensure sterility and compliance at all times. With a view to provide such cutting-edge information within reach of even the SMB pharma sector, this book – Microbiology and Sterility Assurance in Pharmaceuticals and Medical Devices – has been launched. This book therefore represents an unparalleled and unprecedented text in the field of pharmaceutical and medical device microbiology. This book not only covers subject matter and technical content which is established as best practices, but also includes content regarded as possible, future and emerging technology or processes.

The book is edited by three people; Madhu Raju Saghee (from India), Tim Sandle (from UK) and Edward C. Tidswell (from USA). Experts from top pharmaceutical companies like Baxter, Johnson and Johnson, Amgen, Pfizer, Patheon, Sartorious, Gador, Catalent, British NHS, GE Healthcare and many more top experts from industry and academics have come together to create this collection of knowledge. The list of authors includes chair and members of USP expert committee on Microbiology and Sterility Assurance, president and senior experts in Parenteral Drug Association, ISPE and ASTM. Foreword by Hans van Doorne, Chair of EDQM, Committee on Microbiology.

The text is organized into four distinct sections each with a number of chapters exclusively dedicated to specific subject matter. In each chapter the style and detail varies to reflect the individual expertise and experience of the contributing author, yet maintaining a consistently high caliber of content permitting a superior learning experience for the reader. The book aims to both inform and assist the reader by balancing theoretical understanding with practical application.

The results of 45 years of scientific and technological development are laid down in these 33 chapters. These chapters, all written by international experts, give a vivid picture of today’s pharmaceutical microbiology. The high standard of the chapters makes it an essential reference guide that should be on the shelf of everyone who is involved or interested in this field.

For details visit www.businesshorizons.com or contact info@businesshorizons.com for further information.

###

Business Horizons, Pharmaceutical Publishers, are leading publishers of technical books for the pharmaceuticals and herbal medicine industry, being sold in over 80 countries worldwide.

For more details contact

Business Horizons

G-59, Masjid Moth, GK-2, New Delhi 110048, INDIA

Tel: +91 921206 1554, Fax: +91-11-41637296

Email: info@businesshorizons.com

Website: www.businesshorizons.com

Report Description

The prevalence of diabetes is on the rise across the globe due to increased life expectancy, changing lifestyles, and the rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated 20 million patients in the region requiring diabetes treatment by 2025.

Browse market data tables and in-depth TOC on BRIC Diabetes Drugs Market (2010-2015).
Early buyers will receive 10% customization of reports.

http://www.marketsandmarkets.com/Market-Reports/bric-diabetes-199.html

Diabetes Drugs Market

India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.

Market Estimates and Forecasts

The report categorizes the BRIC Diabetes Drugs market as follows:

• Injectables Market: (Insulin, exenatide)
• Oral Drugs Market: (Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)

In addition to market tables for each submarket, each section of the report will provide market trends, drivers, and opportunities. The report also draws a competitive landscape, profiling the key players and the top-selling products in the diabetes drug market in BRIC.

What makes our reports unique?

• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
• We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
• We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
• Comprehensive market analysis for the following sectors:
• Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

• Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

Find More Pharmaceuticals Reports http://www.marketsandmarkets.com/Market-Reports/bric-diabetes-199.html

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

M&M covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website www.marketsandmarkets.com

Contact:
Ms. Sunita
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Email: sales@marketsandmarkets.com

http://www.marketsandmarkets.com

http://marketsandmarkets.wordpress.com/

http://marketsandmarkets.blogspot.com/

Bangalore, India, October 05, 2010; Wipro Technologies the global Consulting, System Integration and Outsourcing business of Wipro Limited (NYSE:WIT) today announced the launch of Wipro Rapid Trials platform to accelerate drug development across the globe.

The Wipro Rapid Trials platform is based on the Oracle Life Sciences software suite of products which is an open standards-based platform for business process integration across drug development life cycle. The platform improves data collection speed and quality by creating a cost effective and secure worldwide infrastructure (based on ISO 9001 and ISO27001 standards). This will enable organizations to conduct global trials without having to worry about IT infrastructure challenges. Wipro provides business process outsourcing services including clinical operations support and managed IT infrastructure to allow clients to achieve their clinical research and development benchmarks.
Furthermore the platform cuts the total cost of ownership by 30-40% as the resources are shared across trials while guaranteeing the highest data security possible, all without having to maintain in-house capital equipment, clinical operations.
Working with Oracle, Wipro has deployed a complete end-to-end clinical development environment which allows their clients to rapidly utilize the platform on a trial-by-trial or a specific time-based pricing model. This unique offering presents a great opportunity to small and mid-sized pharmaceutical sponsors and Contract Research Organizations (CROs) needing to standardize their clinical data collection process and operational parameters across studies and regions without having to compromise on quality. Wipro is now able to on-board new clients in as little as ten weeks with this model as against eight to twelve months earlier.
“Many enterprises find themselves challenged to deliver and standardize Electronic Data Management and Data Capture processes across their partner channels that often span multiple geographies,” said Neil de Crescenzo, Senior Vice President & General Manager, Oracle’s Health Sciences Global Business Unit. “Leveraging Oracle products, like Oracle Clinical, Oracle Remote Data Capture, and Oracle Thesaurus Management System combined with its industry expertise, Wipro is very well positioned to deliver clinical trial services.”
NS Bala, Senior Vice President, Manufacturing & Life Sciences Business Unit, Wipro Technologies said, “This agreement is part of our continued strategy to invest in industry based solutions, innovation and build deep industry expertise along with partners such as Oracle, Pharmasol and Icon Technical Group Inc. The Wipro Rapid Trials solution is developed and designed to maximize the return on investment to the sponsors and provide faster time to market to help them develop drugs faster and safer”.
About Wipro
Wipro Technologies, a division of Wipro Limited (NYSE:WIT) is the first PCMM Level 5 and SEI CMM Level 5 certified global IT services organization. Wipro Technologies was recently assessed at Level 5 for CMMI V 1.2 across offshore and onsite development centers. Wipro is one of the largest product engineering and support service providers worldwide. Wipro provides comprehensive research and development services, IT solutions and services, including systems integration, information systems outsourcing, package implementation, software application management, and datacenter managed services to corporations globally.In the Indian market, Wipro is a leader in providing IT solutions and services for the corporate segment in India, offering system integration, network integration, software solutions and IT services.
Wipro also has a strong presence in niche market segments of consumer products and lighting. In the Asia-Pacific and Middle East markets, Wipro provides IT solutions and services for global corporations. Wipro’s ADS’ are listed on the New York Stock Exchange, and its equity shares are listed in India on the Stock Exchange – Mumbai, and the National Stock Exchange.
For more information, please visit our website at www.wipro.com
About Oracle
Oracle (NASDAQ: ORCL) is the world’s most complete, open, and integrated business software and hardware systems company. For more information about Oracle, visit http://www.oracle.com/
Trademarks
Oracle is a registered trademark of Oracle and/or its affiliates.
Media Contacts:
Wipro Technologies
India:
Radhika Mahadevan
Wipro Technologies
+91- 9945042603
radhika.mahadevan@wipro.com

Satarupa Bhattacharya
Gutenberg Communications
+91 9886033437
Satarupa@gutenbergpr.com
US:
Eric Belove
Wipro Technologies
+ 1 (732).216.6242
eric.belove@wipro.com
Lavanya DJ
Gutenberg Communications
+1 (212).239.8740
lavanya@gutenbergpr.com
UK:
Rahul Kadavakolu
Wipro Technologies
+44 792 020 5496
rahul.kadavakolu@wipro.com
Shalini Siromani
Gutenberg Communications
+44.79.6066.3200
shalini@gutenbergpr.com
Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at http://www.sec.gov/. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.

Go to Source

Android and iPhone Applications Developed for Aras Enterprise Open Source PLM

ANDOVER, Mass. and Solothurn, Switzerland – September 21, 2010 – Aras®, the leading enterprise open source Product Lifecycle Management (PLM) software solution provider, today announced the development of Android and iPhone mobile applications for the Aras Innovator suite of enterprise PLM solutions. The apps, developed by Aras partner Porchys, mark another first for the PLM industry and demonstrate the power of the open innovation enabled on Aras’s advanced PLM platform.

Android and iPhone Apps for Aras PLM

http://aras.com/plm/001175

The apps provide global companies with the ability to extend PLM processes and information to the thousands of mobile users on the go. This first-generation of apps for Android and iPhone smartphones enables users to securely access, manage and edit information in Aras from their mobile device. The apps can be configured and extended to support company-specific processes across a wide variety of industries including high tech electronics, automotive, aerospace, energy, pharmaceutical, healthcare and consumer products such as footwear & apparel and food & beverage.

“The Android and iPhone platforms provide a powerful new way for people across the enterprise to securely participate in PLM processes from anywhere in the world,” said Peter Schroer, President of Aras. “Porchys’s introduction of these innovative mobile applications on our PLM platform is a great example of the benefits of an open source approach and the power of the corporate community.”

About Porchys

Porchys provides services in Web, Software and Mobile Application development with PLM implementation consulting and enterprise systems integration. Porchys works with clients to provide managed service solutions, product development, maintenance and software solution testing based on customer needs and requirements. Porchys relies on an experienced team of professionals to deliver quality solutions that provide a significant return on investment. For additional information visit www.porchys.com

About Aras

Aras® Aras is the leading provider of enterprise open source Product Lifecycle Management (PLM) software solutions. Freedom from licensing eliminates up-front expenses and per user costs while superior technology makes Aras the most advanced enterprise PLM solution suite available. Customers include Motorola, Rolls-Royce, Freudenberg, Lockheed Martin, Ingersoll Rand, Klöckner Desma, Hi-P and ACCO Brands. Aras is privately held with global headquarters in Andover, Mass. For additional information visit www.aras.com

Product and service names mentioned herein are the trademarks of their respective owners.

Poorvanchal Systems Pvt Ltd
Email:info@porchys.com
Tel:+91-20-27276502

eClinicalWorks Partners with Array Networks for Data Center Scalability
Application delivery and acceleration solution improves customer response time for healthcare IT service provider

BANGALORE / MUMBAI, India – September 16, 2010 – Array Networks Inc., a global leader in secure application delivery, today announced that eClinicalWorks®, a market leader in ambulatory clinical systems, is now using Array Networks’ AppVelocity (APV)  server load balancer and application delivery controller to support its medical record and management solutions for health care providers. eClinicalWorks’ customers now benefit from increased productivity with a boost in customer response time for clinical tasks while providing secure, reliable 24×7 access for health care providers.

eClinicalWorks selected the Array APV platform to ensure a dependable solution for its cloud hosted application infrastructure.  Customers are benefitting from an enhancement in medical practice productivity while reducing costs and keeping confidential patient records secure. Physicians, health centers and hospitals who are eClinicalWorks’ customers use the solution to manage patient records and maximize healthcare quality with the registry reporting and clinical support features. This cloud hosted solution also enables physicians and other medical personnel to effectively access patient records anywhere to communicate with referring physicians or share consult notes and clinical data.

“We selected Array’s solution because it enhances our software offering and allows our customers to increase productivity without sacrificing patient care or security,” said Matthew Lewis, director of I.T. for eClinicalWorks.

Array Networks’ APV application delivery controllers provide constant, SSL encrypted access to the eClinicalWorks software applications. The load balancing feature efficiently distributes web and application traffic for high availability and minimal down-time which results in reducing common query operations by 50% and decreasing server side connections by as much as fifteen times. In addition, the APV product line exceeds HIPAA and Sarbanes-Oxley Standards.

“We are pleased to work with a company that provides such an important service to the healthcare industry,” said said Sunil Cherian, vice president of product marketing for Array Networks. “After thorough testing in Dell Computer’s technology lab, the APV product received certification approval by eClinicalWorks – once again demonstrating our proven track record in enterprise secure application delivery.”

# # #

About Array Networks

Founded in 2000, Array Networks is a global leader in enterprise secure application delivery and universal access solutions for rapidly growing SSL VPN and application acceleration markets. More than 3,500 customers worldwide – including enterprises, service providers, government and vertical organizations in healthcare, finance, insurance and education – rely on Array to provide anytime, anywhere secure and optimized access. Industry leaders including Deloitte, Red Herring, and Frost and Sullivan have recognized Array as a market and technology leader. Website: www.arraynetworks.net

About eClinicalWorks

eClinicalWorks® is a privately held leader in the ambulatory clinical systems market.  The company’s unified electronic medical record (EMR) and practice management (PM) solutions are proven for every market segment: large practice groups, including Massachusetts eHealth Collaborative (MAeHC), Electronic Health Records of Rhode Island (EHRRI) and the New York City Department of Health and Mental Hygiene, as well as medium, small and solo practices regardless of specialty. The company enjoys high profitability with a five-year compounded growth rate of more than 100 percent year-to-year. With an established customer base of more than 40,000 providers and 120,000 healthcare professionals across all 50 states, eClinicalWorks has been awarded multiple top industry honors including being named to the Inc. 500 in 2009, 2008 and 2007. Based in Westborough, Mass., eClinicalWorks has additional offices in New York City, Pleasanton, Calif., and Alpharetta, Ga. More information on eClinicalWorks can be found at www.eclinicalworks.com or by calling 866-888-MYCW.

For Immediate Release

Press & media contact:

Sharmee Roy

CHANGE AGENTS PR for Array Networks

+91.11.45872326, +91.9999953522

Sharmee.Roy@ChangeAgents.in